The Committee for Medicinal Products for Human Use has given positive opinions to a new drug for depression developed by H. Lundbeck A/S, and one for pulmonary arterial hypertension (PAH) by Actelion Ltd. The decisions were announced on 25 October. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
